Navigation Links
ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference

Kelly Larrabee, Director, Clinical Services, will lead a panel of life sciences executives on the topic of "Capitalizing on Trends in Negotiation, Contracts, and Risk and Reward." Discussion will center around risk/reward approaches and technology collaboration among clinical trial sponsors and service providers such as clinical research organizations.

Washington, DC (PRWEB) July 14, 2009 -- ClearTrial (, a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kelly Larrabee, Director, Clinical Services, will lead a panel of life sciences executives on the topic of "Capitalizing on Trends in Negotiation, Contracts, and Risk and Reward." The panel discussion, taking place this week at the ExL Effective Business Development for Clinical Trial Service Providers conference in the nation's capital, will give attendees the opportunity to gain practical guidelines for successful trial sponsor/service provider agreements, including the latest trends in bundling services and collaborative technology partnerships.

In addition, attendees will discover:

  • How contracting approaches and processes -- such as RFP review, contract structure, metrics and oversight -- have changed due to industry conditions.
  • How service providers are successfully utilizing methodologies from other industries for direct cost savings, including lean six sigma, activity-based costing, and earned value management.
  • The effectiveness of outcomes-based pricing: risk-based services versus fixed price.
For more information on the conference, visit

Larrabee brings more than 17 years of clinical operations and clinical project management experience, with both trial sponsors and service providers, to the ExL conference. Prior to joining ClearTrial, she was Associate Director, Clinical Operations for Quintiles, where she oversaw the management of Clinical Research Associates for the Functional Service Provider group for a global sponsor company and led process improvement initiatives related to managing the closure of non-enrolling sites. Before Quintiles, Larrabee was Manager and Regional Study Lead for Pfizer, where she directed project site protocol deliverables for pilot, phase I and phase II oncology studies, and managed the Pfizer Investigator Training Program for the Western Region. Previously, she was Manager, Research Compliance for MD Anderson Cancer Center.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
2. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
3. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
4. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
5. ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
6. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
7. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
8. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
9. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
10. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
11. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
(Date:6/22/2016)... Research and Markets has announced the addition of the "Biomarkers: ... The global biomarkers market has grown ... market is expected to grow at a five-year compound annual growth ... billion in 2015 to $96.6 billion in 2020. ... 2020) are discussed. As well, new products approved in 2013 and ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):